Denali Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on March 16, 2018, by Denali Therapeutics Inc., a Delaware corporation. The filing primarily reports on the appointment of a new director and references the company's financial results for the fourth quarter and full year ended December 31, 2017, which were announced via press release on March 19, 2018.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K.
Material Changes and Corporate Governance
On March 16, 2018, the Company appointed Mr. Peter Klein to its Board of Directors and as Chair of the Audit Committee. Mr. Klein, formerly the CFO of Microsoft Corporation and William Morris Endeavor Entertainment, LLC, will serve as a Class II director with a term expiring at the 2019 annual meeting.
Compensation and Equity Arrangements
- Cash Compensation: Mr. Klein will receive $40,000 annually for Board service and an additional $15,000 annually for serving as Audit Committee Chair, payable quarterly in arrears.
- Initial Equity Grant: On March 16, 2018, Mr. Klein was granted an option to purchase common stock with a grant date value of $600,000. Vesting occurs at 25% on the one-year anniversary and 1/48th monthly thereafter, contingent on continued service.
- Future Equity Policy: Non-employee directors serving six months or more by the annual meeting are eligible for automatic annual option grants valued at $350,000, vesting fully within one year.
Outlook and Risks
The filing does not contain specific management commentary on future outlook, risks, or contingencies beyond the standard incorporation of the press release. The Company is designated as an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 19, 2018) for specific Q4 and full-year 2017 financial results (revenue, net loss, cash position).
- Verify the vesting schedule and grant date value of the $600,000 option award granted to Peter Klein.
- Confirm the Company's cash runway and burn rate as disclosed in the referenced press release, given the lack of revenue data in this filing.
- Check for any subsequent filings regarding the Company's pipeline progress or clinical trial updates following the March 2018 reporting period.